Researchers at the University of Copenhagen identified proteins produced by common gut bacteria that modulate host metabolism in rodents, including enhanced glucose regulation, appetite suppression, and increased fat burning. These polypeptides influence hormone levels such as GLP-1 and PYY, demonstrating potential for novel pharmabiotic therapies targeting cardio-metabolic disorders. Ongoing clinical trials are investigating live bacteria or isolated proteins to translate these findings into human treatments.